Zozulia A A, Shchurin M R, Dikaia V I, Bondar' V V, Krym N M, Panteleeva G P
Zh Nevrol Psikhiatr Im S S Korsakova. 1994;94(1):61-5.
Depressed patients and healthy donors received dalargin. As shown by the radioreceptor test, the patients recovered normal quantitative and qualitative values of plasma opioid activity due to this drug which is a synthetic agonist of sigma-type opioid receptors. Lymphocyte proliferative activity (spontaneous and induced by polyclonal mitogens) was not significantly different in the test subjects versus the donors, though in vitro studies revealed multidirectional homeostatic effects of dalargin. It is shown that depressions are associated with defective relationships between functions of the immune and opioid system. Dalargin proved uneffective in the treatment of endogenic psychotic depressions, whereas in reactive neurotic depressions and psychosomatic abnormalities the drug is promising and needs further investigations.
抑郁症患者和健康捐赠者接受了达乐argin。放射性受体测试表明,由于这种作为西格玛型阿片受体合成激动剂的药物,患者血浆阿片样物质活性的定量和定性值恢复正常。尽管体外研究揭示了达乐argin的多向稳态效应,但测试对象的淋巴细胞增殖活性(自发的和由多克隆有丝分裂原诱导的)与捐赠者相比并无显著差异。结果表明,抑郁症与免疫和阿片系统功能之间的关系缺陷有关。达乐argin被证明对内源性精神病性抑郁症治疗无效,而在反应性神经症性抑郁症和心身异常中,该药物具有前景,需要进一步研究。